PortfoliosLab logoPortfoliosLab logo
RZLT vs. JANX
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

RZLT vs. JANX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Rezolute, Inc. (RZLT) and Janux Therapeutics, Inc. (JANX). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, RZLT achieves a 118.22% return, which is significantly higher than JANX's 3.91% return.


RZLT

1D
2.59%
1M
58.46%
YTD
118.22%
6M
151.22%
1Y
25.30%
3Y*
32.38%
5Y*
-16.91%
10Y*
-19.49%

JANX

1D
0.84%
1M
-1.24%
YTD
3.91%
6M
1.77%
1Y
-39.24%
3Y*
4.68%
5Y*
-9.18%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

RZLT vs. JANX - Yearly Performance Comparison


2026 (YTD)20252024202320222021
RZLT
Rezolute, Inc.
118.22%-51.84%393.70%-52.05%-56.69%-61.30%
JANX
Janux Therapeutics, Inc.
3.91%-74.22%398.97%-18.53%-33.25%-41.97%

Correlation

The correlation between RZLT and JANX is 0.28, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.28

Correlation (3Y)
Calculated over the trailing 3-year period

0.26

Correlation (5Y)
Calculated over the trailing 5-year period

0.19

Correlation (All Time)
Calculated using the full available price history since Jun 11, 2021

0.19

Fundamentals

Market Cap

RZLT:

$535.81M

JANX:

$898.63M

EPS

RZLT:

-$0.80

JANX:

-$1.84

PB Ratio

RZLT:

4.59

JANX:

0.95

Total Revenue (TTM)

RZLT:

$0.00

JANX:

$21.61M

Gross Profit (TTM)

RZLT:

-$15.00K

JANX:

$8.44M

EBITDA (TTM)

RZLT:

-$67.00M

JANX:

-$134.03M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

RZLT vs. JANX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RZLT
RZLT Risk / Return Rank: 6262
Overall Rank
RZLT Sharpe Ratio Rank: 5050
Sharpe Ratio Rank
RZLT Sortino Ratio Rank: 7373
Sortino Ratio Rank
RZLT Omega Ratio Rank: 8989
Omega Ratio Rank
RZLT Calmar Ratio Rank: 4949
Calmar Ratio Rank
RZLT Martin Ratio Rank: 4848
Martin Ratio Rank

JANX
JANX Risk / Return Rank: 2222
Overall Rank
JANX Sharpe Ratio Rank: 1818
Sharpe Ratio Rank
JANX Sortino Ratio Rank: 2626
Sortino Ratio Rank
JANX Omega Ratio Rank: 2424
Omega Ratio Rank
JANX Calmar Ratio Rank: 2020
Calmar Ratio Rank
JANX Martin Ratio Rank: 2424
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RZLT vs. JANX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Rezolute, Inc. (RZLT) and Janux Therapeutics, Inc. (JANX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


RZLTJANXDifference
Sharpe ratioReturn per unit of total volatility

+0.73

Sortino ratioReturn per unit of downside risk

+2.08

Omega ratioGain probability vs. loss probability

1.40

0.96

+0.44

Calmar ratioReturn relative to maximum drawdown

0.29

-0.61

+0.90

Martin ratioReturn relative to average drawdown

0.49

-0.89

+1.38

RZLT vs. JANX - Sharpe Ratio Comparison

The current RZLT Sharpe Ratio is 0.20, which is higher than the JANX Sharpe Ratio of -0.53. The chart below compares the historical Sharpe Ratios of RZLT and JANX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

RZLT vs. JANX - Drawdown Comparison

The maximum RZLT drawdown since its inception was -99.63%, which is greater than JANX's maximum drawdown of -83.14%. Use the drawdown chart below to compare losses from any high point for RZLT and JANX.


Loading charts...

Drawdown Indicators


RZLTJANXDifference

Max Drawdown

Largest peak-to-trough decline

-99.63%

-83.14%

-16.49%

Max Drawdown (1Y)

Largest decline over 1 year

-87.20%

-64.94%

-22.26%

Max Drawdown (3Y)

Largest decline over 3 years

-87.20%

-81.78%

-5.42%

Max Drawdown (5Y)

Largest decline over 5 years

-95.38%

-83.14%

-12.24%

Max Drawdown (10Y)

Largest decline over 10 years

-99.16%

Current Drawdown

Current decline from peak

-97.43%

-78.54%

-18.89%

Average Drawdown

Average peak-to-trough decline

-87.04%

-52.75%

-34.29%

Ulcer Index

Depth and duration of drawdowns from previous peaks

51.68%

44.34%

+7.34%

Volatility

RZLT vs. JANX - Volatility Comparison

Rezolute, Inc. (RZLT) has a higher volatility of 23.54% compared to Janux Therapeutics, Inc. (JANX) at 9.32%. This indicates that RZLT's price experiences larger fluctuations and is considered to be riskier than JANX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


RZLTJANXDifference

Volatility (1M)

Calculated over the trailing 1-month period

23.54%

9.32%

+14.22%

Volatility (6M)

Calculated over the trailing 6-month period

68.65%

29.29%

+39.36%

Volatility (1Y)

Calculated over the trailing 1-year period

126.23%

73.99%

+52.24%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

95.69%

130.71%

-35.02%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

160.75%

131.25%

+29.50%

Dividends

RZLT vs. JANX - Dividend Comparison

Neither RZLT nor JANX has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

RZLT vs. JANX - Financials Comparison

This section allows you to compare key financial metrics between Rezolute, Inc. and Janux Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.002.00M4.00M6.00M8.00M10.00M202220232024202520260
3.73M
(RZLT) Total Revenue
(JANX) Total Revenue
Values in USD except per share items

Frequently Asked Questions


RZLT and JANX have a correlation of 0.28, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

RZLT has higher volatility (23.54%) compared to JANX (9.32%). In terms of maximum drawdown, RZLT dropped -99.63% vs JANX's -83.14%.

RZLT currently has the higher Sharpe Ratio (0.20 vs -0.53), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for RZLT and JANX

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer